ライフサイエンスコーパス: noninducible

1 rred (16 in the inducible group and 9 in the noninducible).

2 eas pilsicainide plus dofetilide rendered AF noninducible.

3 nts had at least 1 VT terminated or rendered noninducible.

4 riants of Gal3 or Gal80 render the GAL genes noninducible.

5 hich is metal inducible, and cdr-6, which is noninducible.

6 adiofrequency ablation rendered clinical VTs noninducible.

7 cantly worse prognosis than do those who are noninducible.

8 uced by betac signaling, while the other was noninducible.

9 after 180 days of follow up: 19% when VT was noninducible, 42% if nonclinical VT was inducible, 75% w

10 Ablation at these sites rendered Vt/VF noninducible (7 of 9 patients [78%]; 95% confidence inte

11 with EF>30% and 13 (41%) with EF</=30% were noninducible after ablation (P=0.386).

12 ) for which no isthmus was identified became noninducible after ablation of a targeted VT.

13 ht explain why non-targeted VTs might become noninducible after ablation of other VTs.

14 ree survival rates were observed in patients noninducible after scar dechanneling (log-rank P = 0.013

15 enes, including inducible, constitutive, and noninducible alleles of MAL23, MAL43, MAL63, and mal64.

16 a collection of inducible, constitutive, and noninducible alleles.

17 Event-free survival rates in noninducible and inducible patients at 1, 5, 10, and 15

18 Although the noninducible and predominantly nuclear PA28gamma complex

19 oviral systems encoding GnT-V that used both noninducible and tetracycline-inducible promoters.

20 Of the 19 VTs, eight were rendered noninducible and three were modified to a longer cycle l

21 ycardias; ablation rendered the tachycardias noninducible and without recurrence during 1-year follow

22 rified AS alpha isoenzymes revealed that the noninducible AS alpha 2 of R. graveolens is strongly fee

23 kes it a suitable screening tool to reassure noninducible asymptomatic individuals.

24 The 13 animals without inducible VT remained noninducible at the subsequent studies.

25 th paroxysmal AF, AF usually can be rendered noninducible by additional ablation at sites of fraction

26 se ventricular tachycardia (VT) was rendered noninducible by catheter ablation.

27 rospective study, we targeted documented but noninducible clinical VTs based on stored implantable ca

28 ere targeted, and in the second 33 patients, noninducible clinical VTs were also targeted by pace-map

29 d cardiac death was 31% (95% CI, 0%-60%) for noninducible compared with 39% (95% CI, 27-52) for those

30 effect is specific, as A20 does not block a noninducible, constitutively expressed reporter, Rous sa

31 overlapping and nonoverlapping roles for the noninducible costimulatory receptor CD28 and the inflamm

32 ated subunits closely matched those of their noninducible counterparts, suggesting that subunit swapp

33 ible beta-oxidation system and also a second noninducible D-hydroxy-specific beta-oxidation system.

34 ts in three dogs with inducible VT and three noninducible dogs was mapped with a high-resolution elec

35 y inducible gene, COX-1 is widely known as a noninducible gene and is constitutively expressed in a v

36 In NahG and nim1 (for noninducible immunity) Arabidopsis plants, which normall

37 The NIM1 (for noninducible immunity) gene product is involved in the s

38 on and scar modification, the arrhythmia was noninducible in 19 patients (91%).

39 In group 3, AF was rendered noninducible in 27 of 30 patients (90%).

40 le in any patient, and all VTs were rendered noninducible in 63% of the patients.

41 Ventricular tachycardia was noninducible in 85% of patients post ablation, and 71% r

42 ontaneous LLR in 3 patients and rendered LLR noninducible in all patients.

43 Rather, GCN4 translation is noninducible in prt1-1 cells, and genetic analysis indic

44 toff <=0.1 m/s differentiated inducible from noninducible infarctions (P=0.015).

45 d 0.36 for inducible (likelihood ratio+) and noninducible (likelihood ratio-) patients, respectively.

46 Noninducible MADIT II study subjects using this electrop

47 ple Myc-tagged Aha1/Myc3 copurifies with all noninducible Mal63 mutant activators tested.

48 Noninducible mal63 mutant proteins bind to Ssa1 alone an

49 The noninducible mox4Delta allele was epistatic to the const

50 complex with Hsp70, Hsp90, and Sti1, whereas noninducible mutant activators bind only with Hsp70 in a

51 C was compared between the inducible MVT and noninducible MVT patient groups.

52 The 12 VTneg animals remained noninducible on day 100.

53 intercaval junction made atrial fibrillation noninducible or tended to shorten the atrial fibrillatio

54 slow pathway in patients with documented but noninducible paroxysmal supraventricular tachycardia (PS

55 hydroxyacyl-CoA dehydrogenase (D-PBE) of the noninducible pathway (L-PBE-/-D-PBE-/-), exhibit severe

56 lyzing straight-chain acyl-CoAs and a second noninducible pathway catalyzing the oxidation of 2-methy

57 onal protein, and thiolase, and (b) a second noninducible pathway catalyzing the oxidation of 2-methy

58 s, a systems approach revealed inducible and noninducible pathways as potential targets.

59 6 [standard error]) was greater than that in noninducible patients (-10.18% +/- 0.38; P < .05).

60 ater (P < .05) in inducible patients than in noninducible patients (1.31 +/- 0.27 vs 0.64 +/- 0.13, r

61 reversed RPA phase more in inducible than in noninducible patients (56.7% versus 45.3%; P=0.02 by chi

62 o years in inducible patients (3.2%) than in noninducible patients (8.6%).

63 hood of experiencing ICD therapy for VT than noninducible patients (p = 0.023).

64 two-year survival rates were 94% and 84% in noninducible patients and 77% and 45% in inducible patie

65 tors and a shorter time to peak Ecc than did noninducible patients in the border zone and adjacent an

66 Both inducible and noninducible patients received an ICD.

67 Noninducible patients with LVEF>30% had a recurrence-fre

68 Noninducible patients with moderately depressed LV funct

69 nts at follow-up (9 of 14 events occurred in noninducible patients).

70 ection fraction > or =30% and only 42% among noninducible patients, P=0.002).

71 f deaths in inducible patients versus 46% in noninducible patients, P=0.004).

72 Among noninducible patients, those with additional LP abolitio

73 s 29.4% for inducible patients and 25.5% for noninducible patients.

74 inducible patients was 29.0% versus 19.3% in noninducible patients.

75 on (p = 0.021) in inducible patients than in noninducible patients.

76 achycardia was significantly higher than for noninducible patients.

77 .3 versus 6.2+/-1.6 microV; P=0.003) but not noninducible patients.

78 -term outcome of ICD recipients with that of noninducible patients.

79 In contrast, noninducible Pfiesteria and cryptoperidiniopsoids caused

80 with confirmed toxicity, negative controls (noninducible Pfiesteria strains and a related nontoxic c

81 We demonstrate that the same noninducible phenotype could be the result of perturbati

82 Ablation guided by pace-mapping of noninducible postinfarction clinical VTs based on ICD-el

83 Retrograde breakthrough points in 6 noninducible preparations were clustered near the apex o

84 findings provide support for MT3 acting as a noninducible regulator of the nervous system compared wi

85 n was constitutive, the fucPIK operon became noninducible such that the mutant could no longer grow o

86 d enzyme of this classical pathway or of the noninducible system had no such discernible effects.

87 If VT was noninducible, the dense scar (<0.5 mV) region was isolat

88 IFAT targets that render the inFAT substrate noninducible to VT, including VTs that arise postablatio

89 For the noninducible versus inducible patients, LV ejection frac

90 ity for monomorphic ventricular tachycardia (noninducible versus inducible: 13+/-9 versus 19+/-8 g, P

91 Furthermore, patients with noninducible VT had a lower VT recurrence rate than did

92 classified as VTpos (inducible VT) or VTneg (noninducible VT) at day 8.

93 rtality was reached in 9 patients (15%) with noninducible VTs versus 11 patients (34%) with inducible